{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=14", "query": { "condition": "Advanced Solid Tumour", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 3366, "total_pages": 337, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=15&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Solid+Tumour&page=13&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-15T09:30:11.737Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00024141", "title": "Irinotecan Followed by Fluorouracil in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "irinotecan hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-05", "completion_date": "2003-01", "has_results": false, "last_update_posted_date": "2011-03-07", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00024141" }, { "nct_id": "NCT03028103", "title": "Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diffuse Large B Cell Lymphoma", "Primary Mediastinal Lymphoma", "Mantle Cell Lymphoma", "Advanced Solid Tumor", "Marginal Zone Lymphoma" ], "interventions": [ { "name": "Tazemetostat", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Repaglinide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Epizyme, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-03-27", "completion_date": "2019-11-29", "has_results": true, "last_update_posted_date": "2023-06-26", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 3, "location_summary": "Tucson, Arizona • Tampa, Florida • New York, New York", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03028103" }, { "nct_id": "NCT00005642", "title": "SU5416 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "semaxanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2000-05", "completion_date": "2005-11", "has_results": false, "last_update_posted_date": "2010-06-11", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005642" }, { "nct_id": "NCT03490669", "title": "Study to Evaluate Safety, PK, PD, Immunogenicity & Antitumor Activity of MSC-1 in Patients With Adv Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Pancreatic Cancer", "Non Small Cell Lung Cancer", "Ovarian Cancer" ], "interventions": [ { "name": "MSC-1", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 41, "start_date": "2018-05-21", "completion_date": "2019-09-23", "has_results": false, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Grand Rapids, Michigan • Middletown, New Jersey + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Harrison", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03490669" }, { "nct_id": "NCT03129139", "title": "A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Gastric Cancer", "Breast Cancer", "Pancreatic Cancer", "Prostate Cancer Metastatic", "Colo-rectal Cancer", "Solid Tumor", "Solid Carcinoma", "Solid Carcinoma of Stomach", "Cancer of Stomach" ], "interventions": [ { "name": "Minnelide™Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Minneamrita Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2017-10-10", "completion_date": "2024-12-01", "has_results": false, "last_update_posted_date": "2023-10-18", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 7, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 4 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03129139" }, { "nct_id": "NCT02900157", "title": "Study to Evaluate the Safety and Pharmacokinetics of MEDI9090 in Subjects With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "MEDI9090", "type": "BIOLOGICAL" }, { "name": "Durvalumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MedImmune LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 42, "start_date": "2016-08-09", "completion_date": "2020-01-23", "has_results": false, "last_update_posted_date": "2021-01-14", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 5, "location_summary": "Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 2 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Huntersville", "state": "North Carolina" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02900157" }, { "nct_id": "NCT03881488", "title": "Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Solid Tumor", "Metastatic Cancer", "Non-small Cell Lung Cancer", "Small Cell Lung Cancer", "Mesothelioma", "Melanoma", "Head and Neck Cancer" ], "interventions": [ { "name": "CTX-471", "type": "DRUG" }, { "name": "Pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Compass Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2019-05-17", "completion_date": "2025-05-21", "has_results": true, "last_update_posted_date": "2026-10-09", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 10, "location_summary": "Ocala, Florida • Port Saint Lucie, Florida • Boston, Massachusetts + 6 more", "locations": [ { "city": "Ocala", "state": "Florida" }, { "city": "Port Saint Lucie", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03881488" }, { "nct_id": "NCT07277270", "title": "A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms" ], "interventions": [ { "name": "GSK5764227", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2025-12-03", "completion_date": "2030-05-01", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 5, "location_summary": "Reunion, Florida • New Hyde Park, New York • Philadelphia, Pennsylvania + 2 more", "locations": [ { "city": "Reunion", "state": "Florida" }, { "city": "New Hyde Park", "state": "New York" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07277270" }, { "nct_id": "NCT04872166", "title": "A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Breast Cancer" ], "interventions": [ { "name": "BTX-A51", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Edgewood Oncology Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 112, "start_date": "2021-06-07", "completion_date": "2027-05", "has_results": false, "last_update_posted_date": "2025-01-30", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 6, "location_summary": "Lake Mary, Florida • Sarasota, Florida • Cincinnati, Ohio + 2 more", "locations": [ { "city": "Lake Mary", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Nashville", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT04872166" }, { "nct_id": "NCT03435250", "title": "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Lymphoma" ], "interventions": [ { "name": "AG-270", "type": "DRUG" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Institut de Recherches Internationales Servier", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 123, "start_date": "2018-03-04", "completion_date": "2023-04-20", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-10-15T09:30:11.737Z", "location_count": 6, "location_summary": "New Haven, Connecticut • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03435250" } ] }